Sciencast Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Sciencast Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,192	Closed	-$351K	–	522
2022 Q1	$351K	Sell	2,192 -1,908	-47%	-$277K	0.08%	274
2021 Q4	$537K	Buy	4,100 +822	+25%	+$108K	0.09%	278
2021 Q3	$440K	Sell	3,278 -22	-0.7%	-$3.32K	0.12%	233
2021 Q2	$609K	Sell	3,300 -10,352	-76%	-$1.79M	0.13%	234
2021 Q1	$2.21M	Buy	+13,652	New	+$2.25M	0.44%	62
2020 Q3	–	Sell	-8,904	Closed	-$944K	–	477
2020 Q2	$944K	Buy	8,904 +4,953	+125%	+$548K	0.24%	144
2020 Q1	$393K	Buy	+3,951	New	+$511K	0.11%	131
2019 Q1	–	Sell	-1,950	Closed	-$245K	–	406
2018 Q4	$245K	Buy	+1,950	New	+$289K	0.22%	180
2017 Q4	–	Sell	-2,503	Closed	-$346K	–	364
2017 Q3	$346K	Buy	2,503 +894	+56%	+$135K	0.19%	190
2017 Q2	$250K	Buy	+1,609	New	+$246K	0.14%	266

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Sciencast Management's JAZZ Position: Q2 2022 in Review

Sciencast Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 2,192 shares — an estimated $351K sold.

Sciencast Management first reported a position in JAZZ in Q2 2017 and held it in 10 quarters. The position peaked at $2.21M in Q1 2021. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

Sciencast Management reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Sciencast Management sold 2,192 Jazz Pharmaceuticals shares in Q2 2022, an estimated $351K.
Sciencast Management first reported a position in Jazz Pharmaceuticals in Q2 2017 and held it in 10 quarters.
Sciencast Management's Jazz Pharmaceuticals position peaked at $2.21M in Q1 2021.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on Sciencast Management's 13F filing for Q2 2022, filed 3 Aug 2022.